Moderna and Merck's personalised mRNA vaccine met key goals in a Phase 3 melanoma trial, reducing recurrence and spread and raising hopes for a new generation of cancer vaccines worldwide
Moderna and Merck's personalised mRNA vaccine met key goals in a Phase 3 melanoma trial, reducing recurrence and spread and raising hopes for a new generation of cancer vaccines worldwide
<iframe src="https://hindustansphere.com/embed/cluster/52fc297c5ec4b440c1be29939f4be3bf18cdba87" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Moderna, Merck cancer vaccine scores big win in late-stage melanoma trial"></iframe>
